Development of novel agents for ovarian cancer

Update on Cancer Therapeutics

Volumn 3, Issue 3, 2009, Pages 119-132

  Hennessy, B T ^a   Markman, M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cancer; Chemotherapy; Genomic; Molecular; Novel; Ovarian; Targeted; Therapy

Indexed keywords

5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; AZD 2281; BEZ 235; BRCA1 PROTEIN; BRCA2 PROTEIN; CYTOKINE; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GROWTH FACTOR; JANUS KINASE; JANUS KINASE INHIBITOR; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN KINASE C IOTA; PROTEIN P110; PROTEIN P85; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RAS PROTEIN; SEX HORMONE; SF 1126; STAT PROTEIN; TRANSCRIPTION FACTOR HOXA10; UNCLASSIFIED DRUG; UNINDEXED DRUG; XL 147;

CANCER GENETICS; CANCER MORTALITY; CARCINOGENESIS; CLINICAL TRIAL; EPIGENETICS; EPITHELIUM CELL; FEMALE; GENOMIC INSTABILITY; HUMAN; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; REVIEW;

EID: 63749107211     PISSN: 1872115X     EISSN: 1872115X     Source Type: Journal    
DOI: 10.1016/j.uct.2009.02.001     Document Type: Review

References (96)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M.J., et al. Cancer Statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
2. Lindgren P.R., Cajander S., Bäckström T., Gustafsson J.A., Mäkelä S., and Olofsson J.I. Estrogen and progesterone receptors in ovarian epithelial tumors. Mol Cell Endocrinol 221 (2004) 97-104
3. Fathalla M.F. Incessant ovulation-a factor in ovarian neoplasia?. Lancet 17 (1971) 163
4. Cramer D.W., and Welch W.R. Determinants of ovarian cancer risk. II: Inferences regarding pathogenesis. J Natl Cancer Inst 71 (1983) 717-721
5. González-Martín A., and GEICO Group. Treatment of recurrent disease: randomized trials of monotherapy versus combination chemotherapy. Int J Gynecol Cancer 15 Suppl. 3 (2005) 241-246
6. Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354 (2006) 34-43
7. Bookman MA for the Gynecologic Cancer InterGroup (GCIG). GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG-lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma. J Clin Oncol 2006;24:5002.
8. Rivera E., Lee J., and Davies A. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors. Oncologist 13 (2008) 1207-1223
9. Gordon A.N., Finkler N., Edwards R.P., Garcia A.A., Crozier M., Irwin D.H., et al. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. Int J Gynecol Cancer 15 (2005) 785-792
10. Wright J.D., Hagemann A., Rader J.S., Viviano D., Gibb R.K., Norris L., et al. Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis. Cancer 107 (2006) 83-89
11. Chura J.C., Van Iseghem K., Downs Jr. L.S., Carson L.F., and Judson P.L. Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Gynecol Oncol 107 (2007) 326-330
12. Silverberg S. Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol 19 (2000) 7-15
13. International Federation of Gynecology and Obstetrics. Classification and staging of malignant tumours in the female pelvis. Acta Obstet Gynecol Scand 50 (1971) 1-7
14. Histological typing of ovarian tumours. In: Serov S.F., Scully R.E., and Sobin L.H. (Eds). International histological classification of tumours, No. 9 (1973), World Health Organization, Geneva 17-54
15. Benda J.A., and Zaino R. GOG pathology manual (1994), Gynecologic Oncology Group, Buffalo, NY
16. Shimizu Y., Kamoi S., Amada S., Akiyama F., and Silverberg S.G. Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Cancer 82 (1998) 893-901
17. Shimizu Y., Kamoi S., Amada S., Akiyama F., Hasumi K., and Silverberg S.G. The grader and the typer should be friends: a study of comparative value of histopathologic grading and typing of ovarian epithelial carcinoma [Abstract]. Mod Pathol 11 (1998) 115A
18. Silverberg S.G. Prognostic significance of pathologic features. Curr Top Pathol 78 (1989) 85-109
19. Gershenson D., and Wong K.K. The continuum of serous tumors of low malignant potential and low-grade serous carcinomas of the ovary. ASCO educational book (2007) p. 313-7
20. Hernandez E., Bhagavan B.S., Parmley T.H., and Rosenshein N.B. Interobserver variability in the interpretation of epithelial ovarian cancer. Gynecol Oncol 16 (1984) 117-123
21. Baak J.P.A., Langley F.A., Talerman A., and Delemarre J.F.M. Interpathologist and intrapathologist disagreement in ovarian tumor grading and typing. Anal Quant Cytol Histol 8 (1986) 354-357
22. Stalsberg H., Abeler V., Blom G.P., Bostad L., Skarland E., and Westgaard G. Observer variation in histologic classification of malignant and borderline ovarian tumors. Hum Pathol 19 (1988) 1030-1035
23. Suzuki S., Moore II D.H., Ginzinger D.G., Godfrey T.E., Barclay J., Powell B., et al. An approach to analysis of large-scale correlations between genome changes and clinical endpoints in ovarian cancer. Cancer Res 60 (2000) 5382-5385
24. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
25. Hennessy B.T., and Mills G.B. Ovarian cancer: homeobox genes, autocrine/paracrine growth, and kinase signaling. Int J Biochem Cell Biol 38 (2006) 1450-1456
26. Levine D.A., Bogomolniy F., Yee C.J., Lash A., Barakat R.R., Borgen P.I., et al. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res 11 (2005) 2875-2878
27. Campbell I.G., Russell S.E., Choong D.Y., Montgomery K.G., Ciavarella M.L., Hooi C.S., et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64 (2004) 7678-7681
28. Carpten J.D., Faber A.L., Horn C., Donoho G.P., Briggs S.L., Robbins C.M., et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448 (2007) 439-444
29. Shih Ie.M., and Kurman R.J. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 164 (2004) 1511-1518
30. Risch H.A., McLaughlin J.R., Cole D.E., Rosen B., Bradley L., Fan I., et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 98 (2006) 1694-1706
31. Shaw P.A., Zweemer R.P., McLaughlin J., et al. Characteristics of genetically determined ovarian cancer. Mod Pathol 12 (1999) 124A [Abstract]
32. Stephens P., Edkins S., Davies H., Greenman C., Cox C., Hunter C., et al. A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet 37 (2005) 590-592
33. Sjoblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., et al. The consensus coding sequences of human breast and colorectal cancers. Science 314 (2006) 268-274
34. Orsulic S., Li Y., Soslow R.A., Gutkind J.S., and Varmus H.E. Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell 1 (2002) 53-62
35. Dinulescu D.M., Ince T.A., Quade B.J., Shafer S.A., Crowley D., and Jacks T. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 11 (2005) 63-70
36. Yang G., Rosen D.G., Mercado-Uribe I., Colacino J.A., Mills G.B., Bast Jr. R.C., et al. Knockdown of p53 combined with expression of the catalytic subunit of telomerase is sufficient to immortalize primary human ovarian surface epithelial cells. Carcinogenesis 28 (2007) 174-182
37. Alvero A.B., Fishman D.A., Qumsiyeh M.B., Garg M., Kacinski B.M., and Sapi E. Telomerase prolongs the lifespan of normal human ovarian surface epithelial cells without inducing neoplastic phenotype. J Soc Gynecol Investig 11 (2004) 553-561
38. Auersperg N., Wong A.S., Choi K.C., Kang S.K., and Leung P.C. Ovarian surface epithelium: biology, endocrinology and pathology. Endocr Rev 22 (2001) 255-288
39. Zeimet A.G., and Marth C. Why did p53 gene therapy fail in ovarian cancer?. Lancet Oncol 4 (2003) 415-422
40. Wang T.L., Maierhofer C., Speicher M.R., Lengauer C., Vogelstein B., Kinzler K.W., et al. Digital karyotyping. Proc Natl Acad Sci U S A 99 (2002) 16156-16161
41. Shih IeM, Sheu J.J., Santillan A., Nakayama K., Yen M.J., Bristow R.E., et al. Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. Proc Natl Acad Sci U S A 102 (2005) 14004-14009
42. Hennessy B.T., Nanjunden M., Cheng K.W., Nolden L., and Mills G.B. Ovarian cancer: identification of remodeling and spacing factor 1 (rsf-1, HBXAP) at chromosome 11q13 as a putative oncogene in ovarian cancer (News and Commentary). Eur J Human Genet 14 (2006) 381-383
43. Watanabe T., Imoto I., Kosugi Y., Ishiwata I., Inoue S., Takayama M., et al. A novel amplification at 17q21-23 in ovarian cancer cell lines detected by comparative genomic hybridization. Gynecol Oncol 81 (2001) 172-177
44. Shayesteh L., Lu Y., Kuo W.L., Baldocchi R., Godfrey T., Collins C., et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 21 (1999) 99-102
45. Cheng K.W., Lahad J.P., Kuo W.L., Lapuk A., Yamada K., Auersperg N., et al. The Rab 25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med 10 (2004) 1251-1256
46. Eder A., Sui X., Rosen D., Nolden L.K., Cheng K.W., Lahad J.P., et al. Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and Cyclin E overexpression in ovarian cancer. Proc Natl Acad Sci U S A 102 (2005) 12519-12524
47. Brown L.A., Irving J., Parker R., Kim H., Press J.Z., Longacre T.A., et al. Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas. Gynecol Oncol 100 (2005) 264-270
48. Hughes-Davies L., Huntsman D., Ruas M., Fuks F., Bye J., Chin S.F., et al. EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 115 (2003) 523-535
49. Anand N., Murthy S., Amann G., Wernick M., Porter L.A., Cukier I.H., et al. Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer. Nat Genet 31 (2002) 301-305
50. Schraml P., Schwerdtfeger G., Burkhalter F., Raggi A., Schmidt D., Ruffalo T., et al. Combined array comparative genomic hybridization and tissue microarray analysis suggest PAK1 at 11q13.5-q14 as a critical oncogene target in ovarian carcinoma. Am J Pathol 163 (2003) 985-992
51. Li P., Maines-Bandiera S., Kuo W.L., Guan Y., Sun Y., Hills M., et al. Multiple roles of the candidate oncogene ZNF217 in ovarian epithelial neoplastic progression. Int J Cancer 120 (2007) 1863-1873
52. Kamikihara T., Arima T., Kato K., Matsuda T., Kato H., Douchi T., et al. Epigenetic silencing of the imprinted gene ZAC by DNA methylation is an early event in the progression of human ovarian cancer. Int J Cancer 115 (2005) 690-700
53. Strathdee G., Appleton K., Illand M., Millan D.W., Sargent J., Paul J., et al. Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am J Pathol 158 (2001) 1121-1127
54. Wei S.H., Balch C., Paik H.H., Baldwin R.L., Liyanarachchi S., Li L., et al. Prognostic DNA methylation biomarkers in ovarian cancer. Clin Cancer Res 12 (2006) 2788-2794
55. Sheehan K.M., Calvert V.S., Kay E.W., Lu Y., Fishman D., Espina V., et al. Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics 4 (2005) 346-355
56. Tibes R., Qiu Y., Lu Y., Hennessy B., Andreeff M., Mills G.B., et al. Reverse phase protein array (RPPA): validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoetic stem cells (HSC). Mol Cancer Ther 5 (2006) 2512-2521
57. Hennessy B.T., Lu Y., Poradosu E., Yu Q., Yu S., Hall H., et al. Pharmacodynamic markers of perifosine efficacy. Clin Can Res 13 (2007) 7421-7431
58. Smith D.I. Transcriptional profiling develops molecular signatures for ovarian tumors. Cytometry 47 (2002) 60-62
59. Wu R., Hendrix-Lucas N., Kuick R., Zhai Y., Schwartz D.R., Akyol A., et al. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. Cancer Cell 11 (2007) 321-333
60. Cheng W., Liu J., Yoshida H., Rosen D., and Naora H. Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. Nat Med 11 (2005) 531-537
61. Bookman M.A., Darcy K.M., Clarke-Pearson D., Boothby R.A., and Horowitz I.R. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 21 (2003) 283-290
62. Hennessy B.T., Smith D.L., Ram P.T., Lu Y., and Mills G.B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4 (2005) 988-1004
63. Mills G.B., Kohn E., Lu Y., Eder A., Fang X., Wang H., et al. Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer. Semin Oncol 30 (2003) 93-104
64. Liu J., Yang G., Thompson-Lanza J.A., Glassman A., Hayes K., Patterson A., et al. A genetically defined model for human ovarian cancer. Cancer Res 64 (2004) 1655-1663
65. Macara I.G. Parsing the polarity code. Nat Rev Mol Cell Biol 5 (2004) 220-231
66. Han L.Y., Landen C.N., Trevino J.G., Halder J., Lin Y.G., Kamat A.A., et al. Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma. Cancer Res 66 (2006) 8633-8639
67. Rosen D.G., Mercado-Uribe I., Yang G., Bast Jr. R.C., Amin H.M., Lai R., et al. The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis. Cancer 107 (2006) 2730-2740
68. Silver D.L., Naora H., Liu J., Cheng W., and Montell D.J. Activated signal transducer and activator of transcription (STAT) 3: localization in focal adhesions and function in ovarian cancer cell motility. Cancer Res 64 (2004) 3550-3558
69. Yu Y., Luo R., and Lu Z. Biochemistry and biology of ARHI (DIRAS3), an imprinted tumor suppressor gene whose expression is lost in ovarian and breast cancers. In: Balch W.E., Der C., and Hall A. (Eds). Regulators and effectors of small GTPases. Part D. Ras proteins. Methods in enzymology vol. 407 (2006) 455-467
70. Fong P.C., Boss D.S., Carden C.P., Roelvink M., De Greve J., Gourley C.M., et al. AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I study. J Clin Oncol 26 (2008) 5510
71. Mwanjewe J., Spitaler M., Ebner M., Windegger M., Geiger M., Kampfer S., et al. Regulation of phospholipase D isoenzymes by transforming Ras and atypical protein kinase C-iota. Biochem J 359 (2001) 211-217
72. Tanyi J.L., Morris A.J., Wolf J.K., Fang X., Hasegawa Y., Lapushin R., et al. The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer. Cancer Res 63 (2003) 1073-1082
73. Fang X., Yu S., Tanyi J.L., Lu Y., Woodgett J.R., and Mills G.B. Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophosphatidic acid through a protein kinase C-dependent intracellular pathway. Mol Cell Biol 22 (2002) 2099-2110
74. Szosarek P.W., Grimshaw M.J., Kulbe H., Wilson J.L., Wilbanks G.D., Burke F., et al. Expression and regulation of tumor necrosis factor alpha in normal and malignant ovarian epithelium. Mol Cancer Ther 5 (2006) 382-390
75. Naora H., and Montell D.J. Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer 5 (2005) 355-366
76. Monk B.J., Han E., Josephs-Cowan C.A., Pugmire G., and Burger R.A. Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol Oncol 102 (2006) 140-144
77. Lu C., Thaker P.H., Lin Y.G., Spannuth W., Landen C.N., Merritt W.M., et al. Impact of vessel maturation on antiangiogenic therapy in ovarian cancer. Am J Obstet Gynecol 198 (2008) 477
78. Bagnato A., Salani D., Di Castro V., Wu-Wong J.R., Tecce R., Nicotra M.R., et al. Expression of endothelin 1 and endothelin A receptor in ovarian carcinoma: evidence for an autocrine role in tumor growth. Cancer Res 59 (1999) 720-727
79. Moser T.L., Pizzo S.V., Bafetti L.M., Fishman D.A., and Stack M.S. Evidence for preferential adhesion of ovarian epithelial carcinoma cells to type I collagen mediated by the alpha2beta1 integrin. Intl J Cancer 67 (1996) 695-701
80. Lessan K., Aguiar D.J., Oegema T., Siebenson L., and Skubitz A.P. CD44 and b1 integrin mediate ovarian carcinoma cell adhesion to peritoneal mesothelial cells. Am J Pathol 154 (1999) 1525-1537
81. Bast Jr. R.C., Klug T.L., St. John E., Jenison E., Niloff J.M., Lazarus H., et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. New Engl J Med 309 (1983) 883-887
82. Cannistra S.A., Abu-Jawdeh G., Niloff J., Strobel T., Swanson L., Andersen J., et al. CD44 variant expression is a common feature of epithelial ovarian cancer: lack of association with standard prognostic factors. J Clin Oncol 13 (1995) 1912-1921
83. Strobel T., Swanson L., and Cannistra S.A. In vivo inhibition of CD44 limits intra-abdominal spread of a human ovarian cancer xenograft in nude mice: a novel role for CD44 in the process of peritoneal implantation. Cancer Res 57 (1997) 1228-1232
84. Rump A., Morikawa Y., and Tanaka M. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem 279 (2004) 9190-9198
85. Braly P., Chu C., Collins Y., Edwards R., Gordon A., McGuire W., et al. Prospective evaluation of front-line chemo-immunotherapy (C-IT) with oregovomab (2 alternative dosing schedules) carboplatin-paclitaxel (C-P) in advanced ovarian cancer (OC). J Clin Oncol 25 (2007) 3024
86. Berek J., Taylor P., McGuire W., Smith L.M., Schultes B., and Nicodemus C.F. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol 27 (2009) 418-425
87. Breidenbach M., Rein D.T., Everts M., Glasgow J.N., Wang M., Passineau M.J., et al. Mesothelin-mediated targeting of adenoviral vectors for ovarian cancer gene therapy. Gene Ther 12 (2005) 187-193
88. Merritt W.M., Lin Y.G., Spannuth W.A., Fletcher M.S., Kamat A.A., Han L.Y., et al. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst 100 (2008) 359-372
89. Nicholson S., Gooden C.S., Hird V., Maraveyas A., Mason P., Lambert H.E., et al. Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: a matched analysis. Oncol Rep 5 (1998) 223-226
90. Muggia F., and Kosloff R. Investigational agents for epithelial ovarian cancer. Exp Rev Anticancer Ther 5 (2005) 855-868
91. Li Y., Hu W., Shen D.Y., Kavanagh J.J., and Fu S. Azacitidine enhances sensitivity of platinum-resistant ovarian cancer cells to carboplatin through induction of apoptosis. Am J Obstet Gynecol (2008) [epub ahead of print]
92. Bast R.C., Iyer R.B., Hu W., Kavanagh J., Coleman R.L., Levenback C., et al. A phase IIa study of a sequential regimen using azacitidine to reverse platinum resistance to carboplatin in patients with platinum resistant or refractory epithelial ovarian cancer. J Clin Oncol 26 (2008) 3500
93. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455 (2008) 1061-1068
94. Hennessy B.T., Gonzalez-Angulo A.M., Carey M.S., and Mills G.B. A systems approach to analysis of molecular complexity in breast cancer. Clin Cancer Res 15 (2009) 417-419
95. Leary R.J., Lin J.C., Cummins J., Boca S., Wood L.D., Parsons D.W., et al. Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc Natl Acad Sci U S A 105 (2008) 16224-16229
96. Berns K., Horlings H.M., Hennessy B.T., Madiredjo M., Hijmans E.M., Beelen K., et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12 (2007) 395-402